China Bao Tai, Sinopharm and Lianhua Supermarkets to Distribute Oculus' Microcyn(R)-Based Wound Care Solution in China.Provides for Minimum Purchases of $12 Million During Five-Year Agreement PETALUMA, Calif. -- Oculus oculus (Latin: “eye”) In architecture, any of several elements resembling an eye, such as a round or oval window or the round opening at the top of some domes (see Pantheon). Innovative Sciences, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :OCLS OCLS Off-Campus Library Services ) today announced that it has entered into an exclusive distribution agreement with China Bao Tai Investment Company, Ltd., for the rights to its Microcyn[R]-based wound care solution in China. The non-irritating, oxychlorine compound technology, which is designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores, will be packaged under China Bao Tai's private label brand names in China. The five-year agreement provides for minimum purchases of $12 million of Oculus' Microcyn Technology. China Bao Tai will utilize various sub-distributors for hospitals, independent pharmacies and retail pharmacies. To that end, China Bao Tai has reached agreement with two sub-distributors: Sinopharm for hospital and pharmacy distribution: Sinopharm (www.sinopharm.com/en) is China's largest pharmaceutical group. Incorporating research with production and service trade, the company has under its jurisdiction 10 wholly owned subsidiaries Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. or shareholding companies. In 2004, its sales revenue from medicines and medical equipment totaled RMB RMB Right Mouse Button RMB Regional Management Board (USACE) RMB Rolf Maier Bode (musician, band) RMB Ren Min Bi (currency of People's Republic of China) 18 billion and its imports and exports volume reached $500 million US. "Being the largest pharmaceutical group in China, we see a multitude of evolutionary technologies coming out of the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. ," said Yan Bing, president of Sinopharm. "However, the potent antimicrobial antimicrobial /an·ti·mi·cro·bi·al/ (-mi-kro´be-al) 1. killing microorganisms or suppressing their multiplication or growth. 2. an agent with such effects. nature of the Microcyn Technology in tandem Adv. 1. in tandem - one behind the other; "ride tandem on a bicycle built for two"; "riding horses down the path in tandem" tandem with its 'safe-as-saline' profile is more than an evolutionary improvement--it redefines the rules of engagement in the anti-infective market." Lianhua Supermarkets for supermarket distribution: Lianhua Supermarket Holdings Co., Ltd. (www.lhok.com.cn) is a retail chain operator with retail outlets covering the entire Chinese nation, offering a full range of products through direct operations, franchises, mergers and acquisitions. Lianhua Supermarket operates a total of 3,609 outlets spanning 21 provinces and municipalities across the nation. Hoji Alimi, Oculus president and chief executive officer, said, "This partnership marks another step forward in our efforts to reduce our international costs while increasing our revenues and allowing our organization to focus our resources on the U.S. clinical trials. China Bao Tai is a major distributor to the Chinese market and we are fortunate to have a partner with such a significant presence in this region. In addition, minimum purchasing requirements specified in the agreement should result in a steady stream of payments to Oculus from China Bao Tai, Sinopharm and Lianhua Supermarkets over the life of the agreement." Recent Partnerships In addition to the China Bao Tai agreement, Oculus has finalized two other international partnerships in the past year. These include an agreement with Alkem Laboratories Ltd. of India, the sixth largest pharmaceutical company in that country, which has just successfully concluded the launch of Oxum, an oxychlorine solution for wound treatment based on Oculus' Microcyn Technology. The product is now available for sale in all 22 states in India and Alkem's 850-person direct sales force is in the process of introducing Oxum to over 25,000 practicing physicians and surgeons Physicians and surgeons are medical practitioners who treat illness and injury by prescribing medication, performing diagnostic tests and evaluations, performing surgery, and providing other medical services and advice. . In February of this year, Oculus also announced that it had entered into an exclusive agreement with Dancohr Corporation B.V., a manufacturer and wholesaler of cosmetics, for Dancohr to distribute Courtin(TM) oxychlorine solution (formulated with Oculus' Microcyn Technology) in the U.K., The Netherlands, and other EU member states. This five-year agreement provides for minimum purchases of $10 million US of the Microcyn Technology. About China Bao Tai Investment Company China Bao Tai Investment Co., Ltd. is a diversified investment company Diversified investment company An investment vehicle such as a mutual fund that invests in an assortment of securities. with a focus on health care, high-tech, new energy sources, and environmental protection. It is registered with the State Administration for Industry and Commerce of the People's Republic People's Republic n. A political organization founded and controlled by a national Communist party. of China. China Bao Tai has extensive experience introducing new products and technologies into China and enjoys a productive working relationship with both local and central government agencies. About Oculus Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of Microcyn Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus' platform technology, called Microcyn, is a non-irritating, oxychlorine compound that is designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores. Oculus' principal operations are in Petaluma, California Petaluma is a city in Sonoma County, California, in the United States. As of the 2000 census, the city had a total population of 54,538. As of 2005, Petaluma's population is 56,721. [link was dead) contains the Rancho Petaluma Adobe, a National Historic Landmark. , and it conducts operations in Europe and Latin America Latin America, the Spanish-speaking, Portuguese-speaking, and French-speaking countries (except Canada) of North America, South America, Central America, and the West Indies. through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V. Our website is www.oculusis.com. Forward-Looking Statements Except for historical information herein, the matters set forth in this press release are forward-looking within the meaning of the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These forward-looking statements are identified by the use of words such as "will be," "should result," "provides," and "designed," among others. These forward-looking statements are based on Oculus Innovative Sciences, Inc.'s current expectations. Investors are cautioned that such forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business including risks inherent in the development and commercialization of potential products, the risk that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals in China, the Company's future capital needs, and its ability to obtain additional funding and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the quarterly report on Form 10-Q Form 10-Q See 10-Q. for the quarter ended December 31, 2006. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements. Oculus and Microcyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and services marks are the property of their respective owners. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion